Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 September 2016 | By Michael Mezher
The US Food and Drug Administration (FDA) on Friday announced it had approved Amgen's Amjevita (adalimumab-atto), the first biosimilar version of AbbVie's best-selling biologic Humira (adalimumab).
In July, FDA's Arthritis Advisory Committee voted unanimously to support the approval. Despite the approval, FDA did not clear Amgen's biosimilar for all 10 of Humira's indications. According to FDA, both drugs share the following six indications:
However, FDA says that Amjevita is only indicated for juvenile idiopathic arthritis in patients four or older, while Humira is indicated to treat patients as young as two or older. And, unlike Humira, Amjevita is not approved to treat pediatric Crohn's disease, hidradenitis suppurativa or uveitis.
According to FDA, Amjevita is also required to display a boxed warning on its label over the increased risk of serious infections when taking the drug.
As with the three previous US biosimilar approvals, FDA says it has not approved Amjevita to be interchangeable with Humira.
The approval marks the fourth biosimilar approved under the Biologics Price Competition and Innovation Act's 351(k) pathway, which allows sponsors an abbreviated path to market by demonstrating their product is biosimilar to a reference product. In early August, AbbVie filed a lawsuit to stop the marketing of Amgen's biosimilar to Humira and it remains to be seen when Amjevita may hit the US market. Humira first one approval in 2002.
Tags: Humira, Amjevita, Biosimilar, adalimumab, adalimumab-atto
Regulatory Focus newsletters
All the biggest regulatory news and happenings.